SCHEMBL7902807

SCHEMBL7902807

CCOC(=O)c1cc(C)sc1NC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.61
ALDH1A1 P00352 10/20 0.58
MAPT P10636 6/20 0.58
LMNA P02545 3/20 0.58
HPGD P15428 9/20 0.57
GAA P10253 3/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP1A2 P05177 1/20 0.57
GRIN2C Q14957 2/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALOX12 P18054 1/20 0.55
THRB P10828 3/20 0.54
TP53 P04637 2/20 0.54
POLB P06746 1/20 0.54
KDM4E B2RXH2 7/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7904197 0.83 GRIN2C (0.70) NPSR1ALDH1A1MAPTGRIN2CMEN1
SCHEMBL8288620 0.78 ALDH1A1 (0.72) NPSR1ALDH1A1MAPTHPGDCYP2C9
SCHEMBL16707018 0.77 ALDH1A1 (0.62) NPSR1ALDH1A1MAPTLMNAHPGD
SCHEMBL2829793 0.77 ALDH1A1 (0.56) NPSR1ALDH1A1MAPTLMNAHPGD
SCHEMBL5464054 0.76 ALDH1A1 (0.61) NPSR1ALDH1A1MAPTLMNAHPGD
SCHEMBL6108635 0.76 PPARG (0.58) ALDH1A1MAPTLMNACYP1A2MEN1
SCHEMBL9645677 0.75 RAB9A (0.74) NPSR1ALDH1A1MAPTLMNAGAA
SCHEMBL13727690 0.74 ALDH1A1 (0.73) NPSR1ALDH1A1MAPTLMNAHPGD
SCHEMBL571045 0.73 CA12 (0.63) NPSR1ALDH1A1MAPTLMNAHPGD
SCHEMBL10746533 0.73 ALDH1A1 (0.56) NPSR1ALDH1A1MAPTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2019-04-30 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
WO-2010088414-A2 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions GRIN1, GRIN2A, GRIN2B NPSR1 67/4885ALDH1A1 2048/4885MAPT 768/4885
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B NPSR1 67/4885ALDH1A1 2048/4885MAPT 768/4885
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN1, GRIN2A, GRIN2B NPSR1 67/4885ALDH1A1 2048/4885MAPT 768/4885
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH NPSR1 3797/4885ALDH1A1 1977/4885MAPT 2844/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH NPSR1 3797/4885ALDH1A1 1977/4885MAPT 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.